Skip to content

Research on Precision Diagnosis of Urinary System Tumors Based on Multimodal Radiomics and Metabolomics

Research on Precision Diagnosis of Urinary System Tumors Based on Multimodal Radiomics and Metabolomics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111424
Enrollment
Unknown
Registered
2025-10-31
Start date
2025-10-31
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate malignant tumor

Interventions

Gold Standard:Pathology is the gold standard
Index test:Pathology is the gold standard

Sponsors

Ningbo First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Patients with primary malignant tumors of the urinary system diagnosed by pathology;

Exclusion criteria

Exclusion criteria: 1.Merge with other malignant tumors; 2.Severe liver and kidney dysfunction (Child Pugh grade C or eGFR<30ml/min/1.73m ²); 3.Metabolic diseases such as diabetes and cirrhosis; 4.Active urinary system infection; 5.Pregnant or lactating women; 6.Recently taking drugs that may affect metabolism (such as chemotherapy drugs, immunosuppressants, etc.).

Design outcomes

Primary

MeasureTime frame
Pathology is the gold standard;Accuracy;

Secondary

MeasureTime frame
Sensitivity;Specificity;

Countries

China

Contacts

Public ContactZhou Xuanzhen

Ningbo First Hospital

472787871@qq.com+86 574 6573 2509

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026